소화기내과이연재 교수

전문분야
소화기(간)
진료일정
진료일정표
날짜 6(월) 7(화) 8(수) 9(목) 10(금) 11(토)
오전
오후
외래
외래
외래
휴진일정
진료예약
TAG

경력

  • ▶경력
  • 인제대학교 부산백병원 수련의, 내과전공의, 전임의
  • 의학박사
  • 인제대학교 부산백병원 내과 교수
  • 미국 University of Washington Medical Center 방문교수

주요활동

  • 대한내과학회 정회원
  • 대한소화기학회 정회원
  • 대한간학회 정회원
  • 대한소화기내시경학회 정회원
  • 대한간학회 우수논문상 수상

연구업적

  • 최근 3년간 논문
  • 1.An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection. Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik,Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, and Peggy Hwang. Clin Mol hepatol 2019:25(4):400-407.
  • 2.Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance?associated substitution test. Eun Sun Jang, Kyung?Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook Hyang Jeong. J Med Virol 2019:91(12):2158-2165.
  • 3. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. Joong-Won Park, Yoon Jun Kim, Do Young Kim, Si-Hyun Bae, Seung Woon Paik, Youn-Jae Lee, et al. J of Hepatol 2019;70(4):684-691.
  • 4.Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial. Eun Ju Cho, Su Jong Yu, So Young Kwon, Ji-Hoon Kim, Do Young Kim, Won Kim, June Sung Lee, Jin Woo Lee, Youn Jae Lee, Hee Bok Chae, Jung-Hwan Yoon. Drug Des Devel Ther 2018.12;3767-74.
  • 5. Factors Associated with Health-Related Quality of Life in Korean Patients with Chronic Hepatitis C Infection Using the SF-36 and EQ-5D. Jang ES, Kim YS, Kim KA, Lee YJ, Chung WJ, Kim IH, Lee BS, Jeong SH. Gut Liver 2018;12:440-8.
  • 6.Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. 3. Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, et al. Lancet Gastroenterol Hepatol 2018;3:37-46.
  • 7. Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era. Jang ES, Kim YS, Kim KA, Lee YJ, Chung WJ, Kim IH, et al.Gut Liver 2017;11:543-50.
  • 8. Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1. Jia-Horng Kao, Ming-Lung Yu, Cheng-Yuan Peng, Jeong Heo, Chi-Jen Chu, Ting-Tsung Chang, Youn-Jae Lee, et al. J Gastroenterol Hepatol 2017;32:1998-2005.
  • 9. Baracle® vs Baraclude® for 48 weeks in patients with treatment-naive chronic hepatitis B: a comparison of efficacy and safety. Do Young Kim, Ju Hyun Kim, Won Young Tak, Jong Eun Yeon, Joon Hyeok Lee, Jung Hwan Yoon, Youn Jae Lee, et al. Drug Des Devel Ther 2017;11:3145-52.
  • 10. A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Lim YS, Ahn SH, Lee KS, Paik SW, Lee YJ, et al. Hepatol Int. 2016;10:947-55.
  • 11. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis. 8. Kao JH, Tung SY, Lee Y, Thongsawat S, Tanwandee T, Sheen IS, et al. J Gastroenterol Hepatol. 2016;31:1757-65.
  • 12. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. Kao JH, Lee YJ, Heo J, Ahn SH, Lim YS, Peng CY, Chang TT, et al. Liver Int. 2016;36:1433-41.
  • 13. A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. 10. Ahn SH, Lim YS, Lee KS, Paik SW, Lee YJ, Jeong SH, et al. J Viral Hepat. 2016;23:358-65.
  • 14. Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea.11. Lee SS, Jeong SH, Jang ES, Kim YS, Lee YJ, Jung EU, et al.J Med Virol. 2016;88:275-81.
  • 15. Risk Factors for Hepatitis C Virus (HCV) Infection in Areas with a High Prence of HCV in the Republic of Korea in 2013. 12. Sohn HS, Kim JR, Ryu SY, Lee YJ, Lee MJ, Min HJ, et al. Gut Liver. 2016;10:126-32.